Panaxia announces production license of medical cannabis products in Malta
Chosen by Staff Editors on 05-JUN-22
Panaxia Global, the controlling owner of Panaxia Malta (operations) Ltd., a global pharma company that develops, manufactures and markets advanced medical cannabis products of pharmaceutical quality, announced today that it has received an official license from the health authorities in Malta to manufacture finished medical cannabis products.
Production in Malta, following the adaptation of the EU_GMP standard for the facility in January by the European Health Authority, will allow immediate export from Malta and marketing of the company's finished medical cannabis products in accordance with the standards accepted by the European Authorities for the production of medical cannabis products.
Malta Economic Development Agency, Malta Enterprise, assisted and accompanied Panaxia in the stages of its establishment in Malta until the long_awaited license was obtained.
Obtaining this license alongside the recently adopted EU_GMP standard will allow Panaxia to produce medical cannabis_based products at a facility in Malta, which for marketing to certain countries in the world requires registration of the final product in the country of origin as well. Thus, the facility in Malta will allow the export of products also to countries that require registration of the advanced products (e.g., tablets and inhalation products) in the country of origin as a finished products. The largest and most immediate new markets to which the company is targeting are the British market and the Brazilian market.
These exports currently cannot be made from Israel to those countries, in light of the regulations in Israel, which do not allow the registration of such advanced products in Israel. Thus, the advanced products have been submitted for registration in Malta and will be exported from Malta to the destination countries requiring registration in the country of origin.
The medical cannabis market in the UK The UK is one of the most promising markets in Europe, a significant market estimated today with around 1.4 million patients who can have access to medical cannabis. According to estimates by Prohibition Partners in 2021, 23,466 medical cannabis products were issued in the UK to patients in the private market, compared to 278 products issued in 2019. This is a market that is currently mostly a private and uninsured market.
Panaxia is the first and only company that exports and markets inhaled medical cannabis extracts in Germany in particular, and in Europe in general. The company's premium oils are also regularly marketed in Germany and Cyprus.
About Panaxia Global Panaxia is a global pharma company, which develops, manufactures and markets advanced medical cannabis products of pharmaceutical quality. Panaxia Labs Israel Ltd., which is traded on the Tel Aviv Stock Exchange (TASE: PNAX) and Panaxia Malta (Operations) Ltd. are subsidiaries of Panaxia Global. Both companies hold an EU_GMP European production standard from the EU Health Authority, which is required for the commercial production and export of medical cannabis and its products to Europe. Panaxia specializes in the development, production and marketing of complex and advanced cannabis products, based on clinical information and a vast database of tens of thousands of patients.
ablished in 2010 by Dr. Dadi Segal, Dr. Eran Goldberg and Adv. Assi Rotbart, as the cannabis division of the Segal Pharma Group, which has been operating for over four decades, producing more than 600 different pharmaceutical products, and markets them in over 40 countries.
Panaxia Group employs over 100 people.
For further information, please visit the company's website: www.panaxia.co.il
 Prohibition Partners, The European Cannabis Report, 7th Edition
Dr. Dadi Segal, CEO of Panaxia (PRNewsfoto/Panaxia Pharmaceutical Industries)
This article is from the Distribution basket.
Support Our Sponsors